Fig. 1

Cenerimod treatment reduces blood and salivary gland tissue infiltrates in the viral sialadenitis mouse model. A Viral sialadenitis study design in C57BL/6 female mice depicting early and late therapeutic regimens; mice were 12 weeks of age at the time of AdV5 cannulation (day 0). B Blood lymphocyte subsets were quantified at the end of treatment (day 15) by flow cytometry in cenerimod- and vehicle-treated animals. Numbers in the graphs indicate the percent change versus vehicle. C Quantification of salivary gland lymphocytic subset infiltrates at the end of treatment (day 15) by flow cytometry. Cell numbers were normalized to gram salivary gland and shown as a percentage of vehicle. Numbers in the graphs indicate the percent change versus vehicle. B,C Each data point represents the measurement of individual mice from three independent experiments with 3–4 mice per group; horizontal line indicates the median, the box indicates the upper and lower quartiles and the whiskers indicate the minimum and maximum range; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. vehicle group (Mann-Whitney test). Tx, therapeutic; SG, salivary gland; qd, once daily; po, per os